Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Expands Rare Disease R&D With Boston Tie-Up

This article was originally published in The Pink Sheet Daily

Executive Summary

Shire is teaming up with Children’s Hospital Boston to find therapies for rare pediatric diseases in a three-year collaboration that will capitalize on the strengths of both partners.

You may also be interested in...

A New CEO And Perhaps A New Era At Shire: An Interview With Flemming Ornskov

Making his public debut as Shire CEO at the World Orphan Drug Congress, Flemming Ornskov talked with “The Pink Sheet” about his four-month transition period as Angus Russell’s designated successor, how his background in pediatrics may guide business development, and whether he plans to revise the specialty pharma’s business model or hew to his predecessor’s course.

Pfizer Teams With Eight Boston-Area Research Institutions In $100MM Tie-Up

The collaboration is the third in its localized Centers for Therapeutic Innovation project, intended to nudge academics toward commercial projects.

Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets

Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts